Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer sued over marketing of Lipitor
According to Steve Berman, the lead attorney for the proposed class, Pfizer promoted Lipitor by claiming it prevents heart disease in women and the elderly, where no clinical
According to Steve Berman, the lead attorney for the proposed class, Pfizer promoted Lipitor by claiming it prevents heart disease in women and the elderly, where no clinical
Under the agreement MedImmune scientists will work together with leading researchers of the NIAID Laboratory of Infectious Diseases to produce and test versions of MedImmune’s attenuated, live intranasal
This DDP733 phase II trial is a randomized, blinded, placebo controlled study that is enrolling patients with the disorder at multiple centers in Canada and is assessing safety
NBS-101 is being studied as an improved tablet formulation of strontium, which was recently approved in Europe, in the form of strontium ranelate, and launched in several European
The multi-center study will assess the safety, tolerability, pharmacokinetics and viral response to daily subcutaneous administration of AVI-4065 among healthy volunteers and patients with chronic active hepatitis C
The FDA has ceased its review of the application, based on its concerns related to the higher drug content in the Noven generic product versus the branded Duragesic
The concerns are based on a study that showed a 4% incidence of birth defects in children whose mothers took Paxil during the first trimester of pregnancy, compared
Shares in Incyte have been hit hard, tumbling over 40% in the wake of the news. The extra trial is likely to represent a delay in the drug’s
The first study of its kind in the US, this multi-center, randomized trial will compare degenerative disc disease patients who receive the Wallis implant to those who are
To date, more than 200 patients have been treated with velafermin in this trial, and the last patient is expected to be enrolled by the end of September.